Linezolid versus vancomycin for meticillin-resistant Staphylococcus aureus infection: A meta-analysis of randomised controlled trials

International Journal of Antimicrobial Agents

Volumn 41, Issue 5, 2013, Pages 426-433

  An, Mao Mao ^a   Shen, Hui ^a   Zhang, Jun Dong ^a   Xu, Guo Tong ^a   Jiang, Yuan Ying ^a,b  

^a TONGJI UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Linezolid; Meta analysis; Meticillin resistant Staphylococcus aureus; Vancomycin

Indexed keywords

LINEZOLID; VANCOMYCIN;

ADVERSE DRUG REACTION; ARTICLE; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EMBASE; GOLD STANDARD; HUMAN; KIDNEY DYSFUNCTION; MEDLINE; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

ACETAMIDES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DRUG TOXICITY; FEMALE; HUMANS; INCIDENCE; KIDNEY; KIDNEY FUNCTION TESTS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; OXAZOLIDINONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 84876292404     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.12.012     Document Type: Article

References (30)

1. H.W. Boucher, and G.R. Corey Epidemiology of methicillin-resistant Staphylococcus aureus Clin Infect Dis 46 Suppl. 5 2008 S344 S349
2. A.F. Shorr, Y.P. Tabak, V. Gupta, R.S. Johannes, L.Z. Liu, and M.H. Kollef Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia Crit Care 10 2006 R97
3. I.M. Gould, M.Z. David, S. Esposito, J. Garau, G. Lina, and T. Mazzei New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance Int J Antimicrob Agents 39 2012 96 104
4. D.M. Sievert, J.T. Rudrik, J.B. Patel, L.C. McDonald, M.J. Wilkins, and J.C. Hageman Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006 Clin Infect Dis 46 2008 668 674
5. B.P. Howden, J.K. Davies, P.D.R. Johnson, T.P. Stinear, and M.L. Grayson Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection and clinical implications Clin Microbiol Rev 23 2010 99 139
6. S.J. Brickner, M.R. Barbachyn, D.K. Hutchinson, and P.R. Manninen Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious Gram-positive infections J Med Chem 51 2008 1981 1990
7. M.S. Dryden Linezolid pharmacokinetics and pharmacodynamics in clinical treatment J Antimicrob Chemother 66 Suppl. 4 2011 iv7 iv15
8. R.G. Wunderink, M.S. Niederman, M.H. Kollef, A.F. Shorr, M.J. Kunkel, and A. Baruch Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study Clin Infect Dis 54 2012 621 629
9. K.M. Itani, M.S. Dryden, H. Bhattacharyya, M.J. Kunkel, A.M. Baruch, and J.A. Weigelt Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus Am J Surg 199 2010 804 816
10. M.H. Wilcox, K.J. Tack, E. Bouza, D.L. Herr, B.R. Ruf, and M.M. Ijzerman Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study Clin Infect Dis 48 2009 203 212
11. R.G. Wunderink, M.H. Mendelson, M.S. Somero, T.C. Fabian, A.K. May, and H. Bhattacharyya Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus Chest 134 2008 1200 1207
12. S. Kohno, K. Yamaguchi, N. Aikawa, Y. Sumiyama, and S. Odagiri Linezolid versus vancomycin for the treatment of infections caused by methicillin- resistant Staphylococcus aureus in Japan J Antimicrob Chemother 60 2007 1361 1369
13. J. Weigelt, K. Itani, D. Stevens, W. Lau, M. Dryden, and C. Knirsch Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections Antimicrob Agents Chemother 49 2005 2260 2266
14. J.N. Sharpe, E.H. Shively, and H.C. Polk Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus Am J Surg 189 2005 425 428
15. J. Weigelt, H.M. Kaafarani, K.M. Itani, and R.N. Swanson Linezolid eradicates MRSA better than vancomycin from surgical-site infections Am J Surg 188 2004 760 766
16. D.L. Stevens, D. Herr, H. Lampiris, J.L. Hunt, D.H. Batts, and B. Hafkin Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections Clin Infect Dis 34 2002 1481 1490
17. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gøtzsche, and J.P. Ioannidis The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration J Clin Epidemiol 62 2009 e1 e34
18. A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, and D.J. Gavaghan Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
19. K.S. Khan, S. Daya, and A. Jadad The importance of quality of primary studies in producing unbiased systematic reviews Arch Intern Med 156 1996 661 666
20. D. Moher, A.R. Jadad, and P. Tugwell Assessing the quality of randomized controlled trials. Current issues and future directions Int J Technol Assess Health Care 12 1996 195 208
21. A.J. Sutton, K.R. Abrams, D.R. Jones, T.A. Sheldon, and F. Song Methods for meta-analysis in medical research 2000 Wiley Chichester, UK
22. M.E. Falagas, I.I. Siempos, and K.Z. Vardakas Linezolid versus glycopeptide or β-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials Lancet Infect Dis 8 2008 53 66
23. L. Beibei, C. Yun, C. Mengli, B. Nan, Y. Xuhong, and W. Rui Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials Int J Antimicrob Agents 35 2010 3 12
24. A.C. Kalil, M.H. Murthy, E.D. Hermsen, F.K. Neto, J. Sun, and M.E. Rupp Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis Crit Care Med 38 2010 1802 1808
25. D.J. Farrell, R.E. Mendes, J.E. Ross, and R.N. Jones Linezolid surveillance program results for 2008 (LEADER Program for 2008) Diagn Microbiol Infect Dis 65 2009 392 403
26. M. McCollum, S.V. Sorensen, and L.Z. Liu A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients Clin Ther 29 2007 469 477
27. M. Bounthavong, D.I. Hsu, and M.P. Okamoto Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model Int J Clin Pract 63 2009 376 386
28. J. Higgins, S. Thompson, J. Deeks, and D. Altman Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice J Health Serv Res Policy 7 2002 51 61
29. J.A.C. Sterne, and M. Egger Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis J Clin Epidemiol 54 2001 1046 1055
30. S.G. Thompson Why sources of heterogeneity in meta-analysis should be investigated BMJ 309 1994 1351 1355